DAIC

MARCH 13, 2024

CMS previously published a New Technology APC (Ambulatory Payment Classifications) code that covers the CardiAMP Cell Therapy investigational study procedure, including the BioCardia investigational products utilized to perform the study procedure, allowing the study centers to be reimbursed for the study procedure and products.

CMS 111

CMS Heart Failure Reimbursement Quality of Life 111

DAIC

JULY 25, 2024

BioCardia previously confirmed alignment with the United States Food and Drug Administration (FDA) on the design of the 250-patient randomized, controlled trial and the minimum of 12-month primary composite endpoint of all cause death, reduction in major adverse cardiovascular events, and improvement in quality of life.

Heart Failure 111

Heart Failure Quality of Life CMS Reimbursement 111

American College of Cardiology

FEBRUARY 1, 2025

In today's health care landscape, where quality metrics tied to reimbursement have become the standard, clinicians are under increasing pressure to prescribe specific medications. Clinicians working with older patients have witnessed firsthand how polypharmacy can complicate both their care and diminish quality of life.

Cardiovascular Disease 40

Cardiovascular Disease Coronary Artery Disease CMS Hospital 40